GLP1R and type 2 diabetes mellitus: REMD 2.59 is another human GCGR mAb that differs from volagidemab by one amino acid and has shown reduced gluconeogenesis and blood glucose, improved insulin action and glucose tolerance, enhanced lipid oxidation, protection against diabetic cardiomyopathy, and increased GLP-1 production and L-cell number in mouse models of type 2 diabetes [55,56,57].